ClinicalTrials.gg
RecruitingNCT06609876Updated Dec 3, 2024

Donafenib as Adjuvant Therapy Following Ablation for Recurrent HCC

An interventional study of Thermal ablation and Donafenib in Hepatocellular Carcinoma, Microwave Ablation and Donafenib, sponsored by Sun Yat-sen University. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-12-03.

Sponsored by Sun Yat-sen University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
108
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies testing donafenib in Carcinoma, Hepatocellular — 9 open to participants now, 9 under way, none of them phase 3. donafenib · Carcinoma, Hepatocellular.

Planned enrollment
2nd of 18
108 · median 32
Started
2024
with 6 others
No phase
3 of 18
3 open now
Registered
15th of 18
by date

Among the 18 studies testing donafenib in Carcinoma, Hepatocellular, this one is the 2nd largest by planned enrollment, is one of 7 that started in 2024, is one of 3 with no phase, and was the 15th registered.

Carcinoma, Hepatocellular

3,655 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

9 of the 18 studies testing donafenib in Carcinoma, Hepatocellular are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

About donafenib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing donafenib in Carcinoma, Hepatocellular, or all of them as a file.
02

Study summary

This study intends to evaluate the efficacy and safety of low-dose adjuvant donafenib after thermal ablation for early recurrent HCC within Milan criteria.

Read the detailed description

Thermal ablation is available as the major curative treatments for early-stage recurrent HCC. Donafenib was inferior to sorafenib in overall survival in untreated advanced hepatocellular carcinoma. No study has evaluated low-dose donafenib as adjuvant therapy after thermal ablation. There needs further investigation to explore the efficacy and safety of the combination treatment. Thus, the investigators carried out this prospective, randomized, open-label, phase II trial study to find out it.

03

Conditions studied

  • Hepatocellular Carcinoma
  • Microwave Ablation
  • Donafenib
  • Recurrent Tumor
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. were aged 18-75 years;
  2. had recurrent HCC (RHCC) diagnosed by imaging studies, the first or the second RHCC;
  3. RHCC met the Milan criteria, namely single RHCC lesion less than 5 cm in diameter or no more than 3 tumors (each ≤3 cm in diameter);
  4. the early RHCC (recurrent time \<1 year)
  5. patients were unwilling to undergo repeat hepatectomy or liver transplantation;
  6. had well-preserved liver function, i.e., class A or B, and prolonged ≤5 s;
  7. patients had an performance status score ≤1.
  8. Ability to understand the protocol and to agree to and sign a written document.

Exclusion criteria

Exclusion Criteria:

  1. were under 18 years or over 75 years of age;
  2. primary HCC;
  3. recurrent HCC beyond Milan criteria;
  4. RHCC with or macrovascular tumor thrombus
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
108 participants (estimated)

Study arms

  • Experimental
    Thermal ablation

    Patients only accepted thermal ablation (microwave ablation,radiofrequency ablation)

    Procedure: Thermal ablation

  • Experimental
    Microwave ablation plus Donafenib

    Patients accepted thermal ablation (microwave ablation,radiofrequency ablation) plus Donafenib (100mg, bid)

    Procedure: Thermal ablation · Drug: Donafenib

Interventions

  • ProcedureThermal ablation

    Thermal ablation of tumors

  • Donafenib ( 100 mg,bid)

06

What researchers measure

Primary outcomes

  1. Tumor-free survival rate

    Progression was defined as progressive disease after thermal ablation by independent radiologic review according to mRECIST or death from any cause

    Time frame: 24 months

Secondary outcomes

  1. Overall survival (OS)

    OS is the length of time from the date of ablation until death from any cause.

    Time frame: 36 months

  2. Adverse events

    Safety will be evaluated according to the NCI CTCAE Version 4.03. All observations pertinent to the safety of the study medication will be recorded on the CRF and included in the final report.

    Time frame: 36 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Oct 2026, 24 months after the start.

Of 361 non-industry interventional studies with no phase under Carcinoma, Hepatocellular, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 76. This study's planned 24 months is below that.

Counting every sponsor, half of 385 studies reached it within 47 months; a quarter within 23 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 20, 2024
First posted
Sep 24, 2024
StartActual
Oct 1, 2024
Primary completionEst.
Oct 1, 2026
CompletionEst.
Oct 1, 2028
Last update
Dec 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06609876
Responsible party
Zhou Qunfang (Clinical Professor, Sun Yat-sen University) — Principal investigator
First posted
Sep 24, 2024
Start date
Oct 1, 2024
Primary completion
Oct 1, 2026 (estimated)
Completion
Oct 1, 2028 (estimated)
Last update
Dec 3, 2024

Study contacts

Qunfang Zhou, MD
Contact
zhouqun988509@163.com
86 19868000115
Feng Duan, Professor
Contact
duanfeng@vip.sina.com
86 13910984586
Feng Duan, Professor
study director · Chinese PLA General Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Donafenib

Start the discussion